Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | Finanzwire

Basculer en Français

9473	Companies
185388	Keywords
117743	Articles
99274	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 08/06/2025 at 22:10, 3 months 29 days ago

Protagonist Therapeutics' Second Quarter 2025 Financial Results

Financial Results Protagonist Therapeutics Second Quarter 2025 Icotrokinra NDA Rusfertide Phase 3
PRESS RELEASE

published on 08/06/2025 at 22:05, 3 months 29 days ago

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports NDA submission for icotrokinra for PsO treatment, Phase 2b trial for icotrokinra in UC, VERIFY trial data of rusfertide in PV, and financial results for Q2 2025

Financial Results Protagonist Therapeutics Psoriasis Icotrokinra Phase 3 VERIFY Trial
BRIEF

published on 07/21/2025 at 14:10, 4 months 14 days ago

Protagonist Submits NDA for Icotrokinra to FDA

Phase 3 Clinical Trials Protagonist Therapeutics Plaque Psoriasis IL-23 Receptor Icotrokinra NDA
PRESS RELEASE

published on 07/21/2025 at 14:05, 4 months 14 days ago

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
Protagonist Therapeutics submits NDA to FDA for first-in-class icotrokinra oral peptide targeting IL-23 receptor, showing efficacy in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Icotrokinra IL-23 Receptor NDA Submission
BRIEF

published on 06/30/2025 at 22:10, 5 months 4 days ago

Protagonist Therapeutics Introduces PN-477 for Obesity Treatment

Obesity Treatment Protagonist Therapeutics PN-477 Triple Agonist Peptide GLP-1, GIP, GCG
PRESS RELEASE

published on 06/30/2025 at 22:05, 5 months 4 days ago

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
Protagonist Therapeutics announces development candidate PN-477, a triple agonist peptide, targeting GLP-1, GIP, GCG receptors for obesity treatment. IND-enabling studies in progress, Phase I initiation expected in 2Q26

GLP-1 Protagonist Therapeutics PN-477 GIP GCG Receptors
BRIEF

published on 06/26/2025 at 13:10, 5 months 8 days ago

Protagonist Therapeutics to Announce New Oral Obesity Candidate

Conference Call Clinical Studies Protagonist Therapeutics Oral Obesity Candidate Biopharmaceutical Pipeline
PRESS RELEASE

published on 06/26/2025 at 13:05, 5 months 8 days ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Protagonist Therapeutics to host webcast and conference call on June 30th at 4:30 pm ET to announce oral obesity development candidate and study results

Conference Call Webcast Study Results Protagonist Therapeutics Obesity Development
BRIEF

published on 05/21/2025 at 13:10, 6 months 14 days ago

Protagonist Therapeutics to Attend Jefferies Global Healthcare Conference 2025

Biopharmaceuticals Protagonist Therapeutics Rusfertide Healthcare Conference 2025 Icotorokina
PRESS RELEASE

published on 05/21/2025 at 13:05, 6 months 14 days ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Protagonist Therapeutics to present at Jefferies Global Healthcare Conference on June 4, 2025. Learn about company overview and pipeline drug candidates

Biopharmaceutical Company Clinical Studies Protagonist Therapeutics Jefferies Global Healthcare Conference Pipeline Drug Candidates

Accesswire

Published on 12/05/2025 at 02:35, 5 hours 51 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 5 hours 56 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 7 hours 26 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 21 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 26 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 08:05, 21 minutes ago

Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 25 minutes ago

Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 25 minutes ago

Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025
Published on 12/05/2025 at 08:00, 26 minutes ago

Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) approaches the 500-million mark ahead of listing
Published on 12/05/2025 at 08:00, 26 minutes ago

Custodian Property Income REIT plc: Share Buyback

Les Echos

Published on 12/04/2025 at 18:00, 14 hours 26 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 41 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 42 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 14 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE